2-[2-(2-Azidooxyethoxy)ethoxy]ethanamine

• 分子结构分类: 有机化合物 - 有机盐 - 有机叠氮化物
• 英文名称: 2-[2-(2-Azidooxyethoxy)ethoxy]ethanamine
• 英文别名: 2-[2-(2-azidooxyethoxy)ethoxy]ethanamine
• 化学式: C₆H₁₄N₄O₃
• 分子量: 190.202
• InChiKey: JHTSIMZRNJACTK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  13
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  68.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-(2,5-dichloro-4-((3-(4-cyclopropyl-1,2,3,4-tetrahydroquinoxaline-1-carbonyl)pyridin-4-yl)oxy)phenyl)propanoic acid 、 2-[2-(2-Azidooxyethoxy)ethoxy]ethanamine 在 三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二氯甲烷 为溶剂， 以78%的产率得到N-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)-3-(2,5-dichloro-4-((3-(4-cyclopropyl-1,2,3,4-tetrahydroquinoxaline-1-carbonyl)pyridin-4-yl)oxy)phenyl)propanamide
  参考文献：
  名称：

  Discovery of Intestinal Targeted TGR5 Agonists for the Treatment of Type 2 Diabetes

  摘要：

  Activation of TGR5 stimulates intestinal glucagon-like peptide-1 (GLP-1) release, but activation of the receptors in gallbladder and heart has been shown to cause severe on-target side effects. A series of low-absorbed TGR5 agonists was prepared by modifying compound 2 with polar functional groups to limit systemic exposure and specifically activate TGR5 in the intestine. Compound 15c, with a molecular weight of 1401, a PSA value of 223 angstrom(2), and low permeability on Caco-2 cells, exhibited satisfactory potency both in vitro and in vivo. Low levels of 15c were detected in blood, bile, and gallbladder tissue, and gallbladder-related side effects were substantially decreased compared to the absorbed small-molecule TGR5 agonist 2.

  DOI：

  10.1021/jm500829b

文献信息

• ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR
  申请人：Augustyns Koen

  公开号：US20140079632A1

  公开（公告）日：2014-03-20

  The present invention relates to selective trypsine-like serine protease activity-based probes, in particular urokinase plasminogen activator-activity based probes, the use thereof and methods for detecting selective urokinase activity by making use of said probes.

  本发明涉及选择性胰蛋白酶样丝氨酸蛋白酶活性探针，特别是以尿激酶纤溶酶原激活剂活性为基础的探针，其使用和利用该探针检测选择性尿激酶活性的方法。
• COMPOUNDS, DEVICES, AND USES THEREOF
  申请人：SIGILON THERAPEUTICS, INC.

  公开号：US20200039943A1

  公开（公告）日：2020-02-06

  The present invention provides compounds, e.g., compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are implantable elements (e.g., devices and materials) comprising the same, as well as methods of use thereof, e.g., for treating or preventing a disease, disorder, or condition.
• Discovery of Intestinal Targeted TGR5 Agonists for the Treatment of Type 2 Diabetes
  作者：Hongliang Duan、Mengmeng Ning、Qingan Zou、Yangliang Ye、Ying Feng、Lina Zhang、Ying Leng、Jianhua Shen

  DOI：10.1021/jm500829b

  日期：2015.4.23

  Activation of TGR5 stimulates intestinal glucagon-like peptide-1 (GLP-1) release, but activation of the receptors in gallbladder and heart has been shown to cause severe on-target side effects. A series of low-absorbed TGR5 agonists was prepared by modifying compound 2 with polar functional groups to limit systemic exposure and specifically activate TGR5 in the intestine. Compound 15c, with a molecular weight of 1401, a PSA value of 223 angstrom(2), and low permeability on Caco-2 cells, exhibited satisfactory potency both in vitro and in vivo. Low levels of 15c were detected in blood, bile, and gallbladder tissue, and gallbladder-related side effects were substantially decreased compared to the absorbed small-molecule TGR5 agonist 2.